Freddy A. Jimenez sold $19k of CLDX
SVP & GENERAL COUNSEL at Celldex Therapeutics, Inc.. 771 shares at an average of $24.77, traded Aug 13, 2025, filed Aug 15, 2025.
Score components
- +15RoleOfficer
- 0Trade size$19k at market
- 0Share of holdings soldSold 2.2% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -4.1%, 3m +0.2%, 6m -9.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-022069, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 13, 2025 | SOpen-market sale Common Stock | -341 | $23.95 | $8,167 | 35,392 | Aug 15, 2025 |
| Aug 13, 2025 | SOpen-market sale Common Stock | -430 | $25.42 | $11k | 34,962 | Aug 15, 2025 |
Related signals
Other insiders at Celldex Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | CLDXsell Celldex Therapeutics, Inc. | Freddy A. Jimenez SVP & GENERAL COUNSEL | $121k 4,166 shares | -12% | |
| 38Weak | CLDXsell Celldex Therapeutics, Inc. | Richard M. Wright other | $1.2M 49,298 shares | -70% | |
| 45Moderate | CLDXbuy Celldex Therapeutics, Inc. | Anthony S Marucci PRESIDENT & CEO | $308k 11,500 shares | +40% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.